Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -W-
23.11.2015 14:00:00

Mobelife, a Materialise Company, Announces Collaboration with Exactech Australia

Mobelife, a Materialise company specializing in customized implant design and production for challenging bone and joint reconstruction surgery, is proud to announce a collaboration with Exactech Australia, which will bring Mobelife’s complete portfolio of custom implants to the Australian market. Included in this portfolio is Mobelife’s solution for complex glenoid reconstructions in the shoulder, named Glenius.

As the exclusive independent distributor of Exactech Inc. in the Australian market, Exactech Australia is dedicated to providing innovative products and intuitive instrumentation as well as delivering on Exactech’s promise of being "Surgeon focused, patient driven". Through their partnership with Mobelife, Exactech Australia will be able to expand their innovative portfolio of hip and shoulder solutions to specialist surgeons in Australia. Of key importance to Mobelife is that this partnership will maintain the close and dynamic collaboration between the surgeon and Mobelife’s expert team, a key aspect in the design process of both aMace and Glenius hip and shoulder implants, which is completely personalized to both the patient and surgeon.

Tim Clijmans, co-founder and CEO of Mobelife and Director of Global Clinical Direct Sales at Materialise, states, "Mobelife is proud to offer all-in-one unique solutions matching the patient's anatomy and pathology as well as the surgeon's needs in many countries, so it is exciting to now be bringing our full portfolio to Australian surgeons and their patients with Exactech Australia. Given Exactech’s leadership in upper-extremities, it is especially exciting to collaborate with its distributor to bring our novel shoulder reconstruction solution to the region.”

Oliver Johannessen, General Manager of Exactech Australia says, "As a company founded by an orthopedic surgeon, Exactech is uniquely attuned to addressing the clinical challenges that surgeons face. Mobelife’s customized acetabular revision and glenoid reconstruction implants answer today’s surgeon needs for an increasing amount of complex surgeries and thereby complement our drive to improve patient outcomes. We look forward to bringing Mobelife’s innovative implant portfolio directly to surgeons and their patients in Australia.”

About Mobelife
Mobelife NV was founded as part of the Materialise Group. As an integral part of Materialise’s medical applications, Mobelife’s goal is to serve and assist health care providers directly – and patients indirectly – by a completely customized product development process for patient-specific orthopedic implants.

Mobelife’s product design and manufacturing process meets the highest quality standards and their highly specialized team of clinical engineers design each case individually to the needs of the patient. With each unique implant delivered, Mobelife aims at total customer satisfaction. Visit www.mobelife.be for more information.

About Materialise
With its headquarters in Leuven, Belgium, and branches worldwide, Materialise (NASDAQ: MTLS) is a provider of Additive Manufacturing (AM) software solutions and sophisticated 3D printing services in a wide variety of industries, including healthcare, automotive, aerospace, art and design and consumer products. Materialise has been playing an active role in the field of AM since 1990, through its involvement in AM for industrial and medical applications, by providing biomedical and clinical solutions such as medical image processing and surgical simulations and by developing unique solutions for its customers' prototyping, production, and medical needs. For additional information, please visit: www.materialise.com.

* The Glenius reconstruction shoulder system is not commercially available in the US or Canada
* The aMace revision system is not commercially available in the US or Canada

Analysen zu Materialise NV (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Materialise NV (spons. ADRs) 7,05 43,29% Materialise NV (spons. ADRs)